Biogen ALS Drug Showed No Benefit, O'Neill Says

Jan. 3 (Bloomberg) -- Gilmore O’Neill, vice president of clinical development at Biogen Idec Inc., talks with Bloomberg's Meg Tirrell about the company's announcement that its experimental drug for amyotrophic lateral sclerosis failed to help patients in a clinical trial. Biogen sank 1.4 percent to $147.86 at 4 p.m. New York time after saying it will end development of the medicine for ALS, also known as Lou Gehrig’s disease. (Source: Bloomberg)

Most Recent Videos

Will Investors Continue to Hold Yahoo Without Alibaba?
34:24 - Jan. 28 -- By spinning off its stake in Alibaba, Yahoo will remove a key reason for investors to hold the stock -- increasing pressure on CEO Marissa Mayer to revive growth from other assets. Bloomberg’s Tom Giles also reports on Apple’s earnings on reports “In The Loop.”
  • Apple’s Power: iPhone 6, Apple Watch and Lots of Cash
  • How Global News Is Impacting Fed Rate Decisions
  • Apple Revenue Jumps 30% on Strong iPhone Sales